CSE:SILO

Silo Wellness Hires Two Veterans of Lifestyle Marketing and Cannabis Industry to Promote Marley Line of Functional & Psychedelic Mushroom Brand

Silo Wellness Inc. (CSE: SILO), a wellness company in the psychedelics and functional mushroom marketplaces, is pleased to announce the appointment of beer, wine and spirits brand marketing and communications expert, Stuart Kirby, as Vice President of Marketing & Communications as well as cannabis and hemp industries expert, Peter Holzworth, as Vice President of Business Development.

"I am delighted to welcome two very accomplished senior executives to key leadership positions with Silo Wellness," stated Douglas K. Gordon, Chief Executive Officer of Silo Wellness. "With a decorated career in the adult beverage industry marketing some of the most iconic brands in the space, I look forward to Stuart's creativity in delivering and amplifying the Marley licensing agreement we have just recently announced. I am equally excited to welcome Peter, who has tremendous experience in the cannabis and hemp industries, and to having him replicate that success within the psychedelic and functional mushroom category."

Kirby has more than twenty five years of experience with integrated strategic communications, brand public relations and consumer lifestyle marketing. He has overseen the marketing and communications functions for some of the most successful companies in their respective industries, such as the world's leading supplier of wine, E & J Gallo, two leading global PR firms, Edelman and Hill & Knowlton as well as the world's leading adult beverage supplier, DIAGEO.

Anchored to the belief that "with great opportunity comes an equal measure of responsibility," Kirby has led numerous corporate social responsibility efforts from environmental sustainability plans and global responsible consumption initiatives to cause-related marketing campaigns and humanitarian relief operations partnering with non-profit entities such as Amnesty International, Surfrider Foundation, Pan-American Development Foundation, USAID and Habitat for Humanity.

"Throughout my career, I have had the great privilege of being entrusted as steward to some of the most iconic, lifestyle brands in the world. Marketing and publicizing the legacy of Bob Marley – a man, musician and mystic that I have long admired – may be one of the most exciting professional opportunities I have ever been responsible for," commented Kirby. "I look forward to transforming this fast-moving industry with a brand that stands for ‘one love' and translating that universal vision to positively impact the communities and cultures we partner with."

A veteran of the capital markets, cannabis and hemp industries, Holzworth has specialized experience in mergers and acquisitions, big data, compliance and regulatory affairs as well as brand development. As Vice President of Business Development for Silo Wellness, he will introduce and scale the Marley-branded mushroom line to the world by establishing relationships with large-scale distributors in the nutraceutical, nutrition, smoke shop and big-box retail markets.

"It is my great pleasure to be entrusted with the awesome responsibility of taking one of the most beloved brand names in the world and applying my experience from the cannabis industry to scale this business exponentially in the immediate future," exclaimed Holzworth. "I look very much forward to assisting Silo Wellness to lead and expand market accessibility, domestically and abroad, to the functional and psychedelics mushroom category. Given my international contacts, global market experience and new business development acumen, I am here to fast-track Silo's industry leadership position and to scale the Marley brand globally in short order."

Silo Wellness is also pleased to announce the appointment of Kenny Choi to the role of Corporate Secretary, effective immediately. The appointment of Mr. Choi follows the resignation of Mo Yang as the Corporate Secretary of Silo Wellness.

About Silo Wellness

The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion. Silo Wellness intends to introduce new, safe and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness' activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness' products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

For further information, please contact: www.SiloWellness.com

Media Relations:
Stuart Kirby, VP of Marketing & Communications
press@silowellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. Other than statements of historical fact, all statements are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the appointment of officers of Silo Wellness and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Compass Pathways to Participate in December Investor Conferences

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

  • 7 th Annual Evercore ISI HealthCONx Conference: Fireside chat at 10:25am ET on December 3, 2024
  • Piper Sandler 36 th Annual Healthcare Conference: Fireside chat at 3:30pm ET on December 4, 2024

A live audio webcast of these events will be accessible here for 30 days following the events.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

  • Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025
  • COMP006 data will now be announced after 26-week time point, expected in the second half of 2026
  • Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%
  • Cash position of $207 million
  • Conference call October 31 at 8:00 am ET (12:00 pm UK)

Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less

Seelos Announces Second Postponement of its Annual Meeting of Stockholders

Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024 from its originally scheduled date of Friday, September 27, 2024 has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.comSEEL2024 on Monday, November 25, 2024 at 8:00 a.m., Eastern Time . The record date for the Annual Meeting, August 19, 2024 is unchanged and applies to the postponed Annual Meeting.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×